SCHEMBL149469

SCHEMBL149469

O=C1NCCN1c1cccc2c1[nH]c1ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.45
KIF11 P52732 5/20 0.42
POLB P06746 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CYP1A2 P05177 4/20 0.39
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 3/20 0.39
TDO2 P48775 3/20 0.39
BLM P54132 2/20 0.39
GABRP O00591 2/20 0.39
GABRD O14764 2/20 0.39
GABRA1 P14867 2/20 0.39
GABRB1 P18505 2/20 0.39
GABRG2 P18507 2/20 0.39
GABRB3 P28472 2/20 0.39
GABRA5 P31644 2/20 0.39
GABRA3 P34903 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147379 0.78 KIF11 (0.42) KIF11POLBTDP1CYP1A2KDM4E
SCHEMBL148918 0.77 TNKS (0.42) KIF11POLBTDP1CYP1A2KDM4E
SCHEMBL7397905 0.76 SCN9A (0.53) SCN9APOLBTDP1CYP1A2KDM4E
SCHEMBL28336625 0.74 HTR6 (0.58) KIF11CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL29056463 0.73 KIF11 (0.49) KIF11POLBCYP1A2KDM4EMEN1
SCHEMBL20887126 0.73 HSD17B10 (0.50) KIF11POLBCYP1A2KDM4EMEN1
SCHEMBL19915264 0.72 HSD17B10 (0.51) KIF11CYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL28568514 0.72 TLR9 (0.52) KIF11POLBTDP1CYP1A2KDM4E
SCHEMBL28823924 0.71 POLB (0.56) KIF11POLBTDP1CYP1A2KDM4E
SCHEMBL3957395 0.71 SCN9A (0.47) SCN9APOLBCYP1A2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 SCN9A 2128/4885KIF11 4119/4885POLB 3512/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 SCN9A 2128/4885KIF11 4119/4885POLB 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.